The goal of this activity is to raise awareness of the symptoms and burden of non-cystic fibrosis bronchiectasis (NCFBE), as well as new treatment targets. Diagnostic delay leads to a cycle of frequent exacerbations during which the vicious vortex of neutrophil-mediated inflammation and lung damage occurs. New research is providing insights on the pathophysiology of NCFBE, including the role of neutrophilic inflammation and activation of neutrophil serine proteases (NSPs) by mediators, such as dipeptidyl peptidase 1 (DPP-1). Novel treatment approaches for inhibiting DPP-1 in NCFBE offer the potential for improving quality of life and preserving lung function.
Upon completion of this activity, participants should be better able to:
Professor, Medicine
Associate Director, Clinical and Academic Affairs
Co-Director, NYU Bronchiectasis/NTM Clinical and Translational Program
NYU Grossman School of Medicine
New York, United States
Professor, Respiratory Diseases
Humanitas University
Chief, Respiratory Unit
IRCCS Humanitas Research Hospital
Milan, Italy
Staff Member, Department of Respiratory Disease
VITAZ Hospital
Saint-Nicholas, Belgium
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Doreen J. Addrizzo-Harris, MD, FCCP, has relevant financial relationships with AN2 Therapeutics, Boehringer Ingelheim, Hill-Rom, Insmed, Zambon (Grant/Research Support).
Stefano Aliberti, MD, has relevant financial relationships with AstraZeneca Pharmaceuticals LP, AstraZeneca UK Limited, GlaxoSmithKline S.p.A, Insmed, Insmed Ireland Limited, Insmed Italy S.R.L, Physio-Assist (Consultant); BRAHMS GmbH, Chiesi Farmaceutici S.p.A, Fondazione Internazionale Menarini, GlaxoSmithKline S.p.A, Insmed Ireland Limited, Insmed Italy S.R.L (Speaker/Speaker’s Bureau).
Pieter C. Goeminne, MD, PhD, has relevant financial relationships with Boehringer Ingelheim (Advisor); Merck (Consultant); Chiesi USA, Inc. (Grant/Research Support); Insmed (Speaker/Speaker’s Bureau).
Patient participating in this activity has no relevant financial relationship(s) with ineligible companies.
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
For Physicians
RMEI Medical Education, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
To receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at [email protected].
Users must:
To claim MOC points, users must
MOC points will be submitted to ABIM profiles within 6 to 8 weeks of completion.
There is no fee for this educational activity.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Featured RMEI CE Activities
Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources
